Target ALS
Overview
A 501(c)(3) medical research foundation founded in 2013 that is committed to finding effective treatments for Amyotrophic Lateral Sclerosis (ALS). The organization works to accelerate ALS drug discovery and development by funding collaborative research and fostering partnerships between academia, the pharmaceutical/biotech industry, government, and non-profits. It provides researchers with funding and access to critical tools and resources, such as biospecimens and genomic datasets, with no intellectual property restrictions to remove barriers to innovation.
Portfolio Companies
6
Website
targetals.orgInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| NeuroDex | Nov 2024 | Grant | Co-investor |
| NuCyRNA Therapeutics | Jun 2025 | Grant | Co-investor |
| Samsara Therapeutics | Oct 2024 | Grant | Co-investor |
| Mabylon AG | Sep 2024 | Grant | Co-investor |
| AcuraStem | Mar 2026 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Target ALS based?
Target ALS is headquartered in New York City, New York, United States.
When was Target ALS founded?
Founding year information for Target ALS is not publicly available.
How many portfolio companies does Target ALS have?
Target ALS has 6 portfolio companies in Caplight's dataset.
What are some companies in Target ALS's portfolio?
Portfolio companies visible on Caplight include NeuroDex, NuCyRNA Therapeutics, Samsara Therapeutics, Mabylon AG, AcuraStem.
What was Target ALS's most recent investment shown here?
Target ALS's most recent investment in this portfolio sample was in AcuraStem in 2026.
What sectors does Target ALS focus on?
Target ALS focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Target ALS focus on?
Stage focus information for Target ALS is not publicly available.
What is Target ALS's AUM?
Target ALS's assets under management are estimated between $180.6M and $180.6M.